OBJECTIVES: Cardiovascular diseases are the most frequent cause of morbidity and mortality in many countries. That explains why medications for the treatment of cardiovascular diseases are group of drugs with largest consumption, and ACE inhibitors take a large part in the consumption. The aim of this study was to analyze the consumption of prescribed ACE inhibitors, in Serbia during year 2009. METHODS: The data about the use of ACE inhibitors were obtained from the Republic Fund of Health Insurance of the Serbia (RFZO). RESULTS: Total consumption of ACE inhibitors in year 2009 was 176,29 DDD and total financial outlay was 59.772.897,11€. Largest use of plain ACE inhibitors was for enalapril (78,32 DDD), fosinopril (20,09 DDD), ramipril (19,11 DDD) and cilazapril (14,19 DDD). The volume of their consumption is not in accordance with the funding spent for these products. Enalapril, which has the highest percentage of consumption in this group of 44,43%, has 28,73% of total allocated funds, while the consumption for fosinopril amounts to 11,40% while 18,69% of funds within the group is allocated for this drug. In Norway and Sweden, country with developed pharmacotherapeutic practice, highest usage of plain ACE inhibitors was for ramipril and enalapril. In these countries, other more expensive products are significantly less likely to be used. If the consumption structure of ACE inhibitors in Serbia in 2009 was as in Norway, but with the same volume of consumption RFZO would save about 9.500.000,00€ only for plain ACE inhibitors. CONCLUSIONS: Viewed from the perspective of the RFZO, large financial resources would be saved if the structure of the utilized ACE inhibitors in Serbia was more similar to the country with developed pharmacotherapeutic practice.